New MS drug made available early to patients in need
NCT ID NCT04081714
First seen Jan 08, 2026 · Last updated May 22, 2026 · Updated 26 times
Summary
This program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is for people who have relapsing MS, non-active secondary progressive MS, or primary progressive MS. The goal is to provide treatment before the drug is fully approved, while researchers gather more safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas Southwestern
Dallas, Texas, 75235, United States
Conditions
Explore the condition pages connected to this study.